8 results about "Splenocyte" patented technology

The present invention relates to a composition for enhancing immunity, containing, as an active ingredient, a polysaccharide enzyme-treated product derived from a mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora, or a novel purified polysaccharide fraction thereof. The composition for enhancing immunity according to the present invention, comprising the polysaccharide enzyme-treated product of the mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora or the novel purified polysaccharide fraction thereof, is composed of specific types and contents of sugars and significantly increases the activity of macrophages, splenocytes, and NK cells upon application thereto, thereby being applicable as an immunopotentiator or a composition for enhancing immunity.

Described herein is an engineered viral subunit vaccine encoding ASFV capsid proteins (e.g., P72 and Penton) for use in pigs. The vaccine with either P72 or Penton tested in mice elicited significantly higher levels of antigen-specific IgM and IgG, increased frequency of antibody-secreting cells in the bone marrow, and higher quality germinal centers in the spleens of immunized mice. Enhanced T cell responses were also observed, with higher levels of IFN-γ and TNF-α in splenocytes. Immunogenicity assessments in pigs further supported these findings, with both MB-P72 and MB-PN180Q inducing robust B cell and T cell responses. These findings show that expression of capsid proteins P72 and Penton in membrane-bound forms via mRNA preserves their native multimeric structure and enhances their immunogenicity and provides a basis for an effective ASFV vaccine.

The invention belongs to the technical field of bioengineering, and relates to a construction method and application of a multiple myeloma extramedullary lesion mouse model. The method comprises the following steps: performing intravenous injection on a Vk12653 tumor cell suspension at the tail of a C57BL / 6J mouse to construct a Vk * MYC myeloma mouse; feeding Vk * MYC myeloma mice to obtain spleen cells infiltrated by tumors; a fibrinogen alpha chain is knocked out from the whole body of a C57BL / 6J mouse, and splenocytes are transplanted; and continuously culturing to obtain the multiple myeloma extramedullary lesion mouse model. The transplanted animal model provided by the invention can be used for effectively screening multiple myeloma extramedullary metastasis drugs and testing multiple drugs and drug combination, meanwhile, the in-vivo mechanism of multiple myeloma extramedullary metastasis can be more comprehensively and deeply researched by using the model, and a basic support is provided for developing new specific drugs.

The invention discloses a monoclonal antibody, a hybridoma cell strain, a detection kit, a detection method and application, and relates to the technical field of animal epidemic disease prevention and control. According to the invention, a monoclonal antibody is obtained and is obtained by secreting a hybridoma cell strain DRV-4G3 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.46567. The specific monoclonal antibody aiming at the duck reovirus muNS protein is prepared and obtained through an immune mouse and splenocyte fusion technology, the monoclonal antibody can recognize the muscovy duck reovirus and the novel reovirus at the same time, and the method for detecting the duck reovirus is established on the basis of the monoclonal antibody and can be used for large-scale serological detection. And reovirus vaccine immune antibody dynamic monitoring is achieved, and good development and practical application values are achieved.

This invention discloses a method for screening TNFR1-targeting active ingredients in Tremella fuciformis fermentation broth, belonging to the field of active ingredient screening. The method includes: preparing and immobilizing a recombinant TNFR1 extracellular domain protein with a His tag; optimizing the conditions for preparing Tremella fuciformis fermentation broth and removing polysaccharides; subjecting the fermentation broth to affinity incubation with the immobilized protein to specifically capture the binding components; washing to remove impurities and then competitively eluting with imidazole phosphate buffer; finally, separating the TNFR1-targeting active ingredients by the methanol-chloroform method. This method utilizes the specific affinity of the TNFR1 target to efficiently and accurately enrich immunologically active ingredients from the complex Tremella fuciformis fermentation broth. Experiments have shown that the obtained components can significantly promote the proliferation of macrophages and splenocytes, providing a new source of raw materials and technical support for the development of novel immune-enhancing products.

The present invention relates to a composition for treating psoriasis diseases using nano-graphene oxide. It was confirmed that the nano-graphene oxide of the present invention regulates inflammatory immune cell subtypes and tissue-resident memory cells, which are psoriasis-pathogenic immune cells. In addition, in an acute psoriasis animal model, it was confirmed that skin thickness, scaling, and erythema were reduced, and the thickness of the epidermal layer was decreased. Furthermore, it was confirmed that immune cells are regulated by reducing psoriasis-pathogenic immune cells and increasing immunoregulatory cells in splenocytes. Moreover, it was confirmed that mitochondrial functions are regulated by increasing mitochondrial ROS and oxygen consumption rates in psoriasis-pathogenic immune cells.

Compositions for determining the efficacy and / or potency of a vaccine preparation are described herein. Splenocytes from immunized animals are isolated and can be frozen. Upon thawing such cells are activated by exposure to a series of dilutions of a vaccine preparation being tested and a series of dilutions of a reference vaccine with known characteristics. Cells secreting immunogen-specific antibody and cells secreting nonspecific antibody are enumerated, as is the amount of immunogen-specific and nonspecific antibody produced. Comparison between the results from the vaccine preparations provides a measure of relative vaccine efficacy and / or potency.

Described herein is an engineered viral subunit vaccine encoding ASFV capsid proteins (e.g., P72 and Penton) for use in pigs. The vaccine with either P72 or Penton tested in mice elicited significantly higher levels of antigen-specific IgM and IgG, increased frequency of antibody-secreting cells in the bone marrow, and higher quality germinal centers in the spleens of immunized mice. Enhanced T cell responses were also observed, with higher levels of IFN-γ and TNF-α in splenocytes. Immunogenicity assessments in pigs further supported these findings, with both MB-P72 and MB-PN180Q inducing robust B cell and T cell responses. These findings show that expression of capsid proteins P72 and Penton in membrane-bound forms via mRNA preserves their native multimeric structure and enhances their immunogenicity and provides a basis for an effective ASFV vaccine.